CAR-T therapy shown to improve symptoms of autoimmune diseases

12 Dec 2023
www.pmlive.com
Cell TherapyImmunotherapyClinical ResultClinical Study
Results from a study led by the University Hospital Erlangen in Germany have revealed that CAR-T therapy significantly improved the symptoms of autoimmune diseases or made them go away entirely.
First conducted in 2021, previouUniversity Hospital Erlangens with systematic lupus erythematosus (SLE) showed promising results after they all autoimmune diseases.
Affecting around 10% of the global population, autoimmune diseases systematic lupus erythematosus (SLE)e system mistakenly attacks normal cells.
Researchers tested whether CD19 CAR-T cells achautoimmune diseasest of B cells, which trigger autoimmune diseases, eradicate autoimmunity and achieve lasting drug-free remission in autoantibody-dependent AID.
The study enrolled a furtheCD19 CAR-T cells living with SLE, four with systemic sclerosis and autoimmune diseasestory myositiautoimmunity were no longer responding to multiple standard treatments.
Within a week of receiving CAR-T infusions, researchers SLEnd that the systemic sclerosiswere eliminated inflammatory myositis (IIM)ccurred in most patients within a few months.
Additionally, all 15 particCAR-Tng patients were able to stop taking the immune-suppressive drugs to reduce the symptoms of their disease and all three IIM patients went into remission after three months, substantially reducing the activity of their disease.
Overall, the therapy was well tolerated with no treatment-related adverse events reported, with only ten cases of mild cytokine-release syndrome, which IIMan inflammatory side effect of CAR-T therapy, as well as single cases of experienced moderate cytokine-release syndrome and vertigo.
The study’s lead author, Dr Fabian Müller, managing director, Bavarian Cancer Research Institute and the Friedrich-Alexcytokine-release syndromegen-Nuremberg, said: “We have opened up an entirely new route of possibly treating several more diseases.cytokine-release syndromevertigo
“We are hopeful that this is at least as good as autologous boBavarian Cancer Research InstituteCancerplant with substantially fewFriedrich-Alexander University of Erlangen-Nuremberg need to do follow-up studies to confirm these results.”
Researchers have said that further research is required, with a larger group of patients, to determine whether the CAR-T therapy will have long-term benefits for patients living with chronic autoimmune diseases.
Additional clinical trials are currently underway to further test CAR-T cell therapy in patients living with several other autoimmune disorders.chronic autoimmune diseases
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.